In Brief: U.S. Surgical buys Japanese distributor
This article was originally published in The Gray Sheet
Executive Summary
U.S. Surgical buys Japanese distributor: USSC completes acquisition of its Tokyo-based Japanese distributor, Auto Suture Japan, in a cash transaction valued at approximately $61 mil. The deal includes a $12 mil. downpayment made earlier this year, "with the balance to be paid over seven years, interest free," the company says. Auto Suture Japan's "135-person fully trained field sales organization" and other personnel will join USSC's workforce. The company also acquires inventory and "a state-of-the-art laparoscopic training center near Tokyo." USSC estimates the distributor's "current annualized business" to be in the $100 mil. range "with a strong pretax margin," noting that the acquisition "began adding more than $50 mil. in annualized incremental revenue during the second quarter of this year"...
You may also be interested in...
At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use
At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.